Jill Weimer
Seminars
Wednesday 7th October 2026
Beyond Single Biomarkers: AI-Enabled Biosignatures for Disease Monitoring in Rare Neurodegenerative Disorders
2:40 pm
- Discussing efforts to integrate proteomics, metabolomics, lipidomics, imaging, digital phenotyping, longitudinal natural history study data, and patient-reported outcomes into comprehensive biosignatures that provide a multidimensional view of disease progression in rare neurodegenerative disorders
- Exploring how ML approaches enable identification of biologically meaningful biomarker combinations that more sensitively capture disease progression and therapeutic response than traditional single-analyte biomarkers
- Showing future applications ranging from clinical trial readiness and surrogate endpoint development to newborn screening and earlier disease detection in genetically defined disorders
